English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  Chronic inflammatory diseases are common in cats and mesenchymal stem cells ( MSC ) are a promising therapeutic approach for management of these disorders. The purpose of this study was to evaluate the safety of intraperitoneal injection of  MSC  in cats.    Hypothesis  Intrapertioneal injection of autologous  MSC  in cats is safe.    Animals  Ten healthy adult purpose‐bred cats.    Methods  Mesenchymal stem cells were isolated from subcutaneous adipose tissue collected during ovariohysterectomy and characterized for expression of  CD 90,  CD 105 and  CD 44 and trilineage differentiation. Three weeks postoperatively a complete blood count, serum chemistry profile, urinalysis, and abdominal ultrasound were performed. Five cats then received 1 × 10 6  of autologous  MSC /kg of body weight intraperitoneally with ultrasound guidance; 5 additional cats were sham injected. Cats were monitored for 6 weeks with daily physical examinations and weekly clinicopathological evaluations. Abdominal ultrasonography was repeated at weeks 1 and 5 after injection.    Results  Serious adverse effects were not observed in any  MSC ‐injected cat. Two animals developed transient lethargy and decreased activity. Jejunal lymph node size was increased in  MSC ‐injected cats compared to controls at weeks 1 (1.38 ± 0.25 versus 0.88 ± 0.25 cm 2 ;  P  = .036) and 5 (1.75 ± 0.82 versus 0.79 ± 0.12 cm 2 ;  P  = .047). A hyperechoic renal segmental cortical lesion was observed in 1  MSC ‐injected cat.    Conclusions and Clinical Relevance  Intraperitoneal  MSC  injection was well tolerated with only mild, self‐limiting adverse effects being observed in 2 cats. This route provides a safe means of administration for cell‐based treatment in cats.

Safety of Intraperitoneal Injection of Adipose Tissue‐Derived Autologous Mesenchymal Stem Cells in Cats